<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="55338">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01918332</url>
  </required_header>
  <id_info>
    <org_study_id>LG-VRCL002</org_study_id>
    <nct_id>NCT01918332</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Valsartan 160mg and Rosuvastatin 20mg in Patients With Hypertension and Hyperlipidemia</brief_title>
  <official_title>A Multicenter, Randomized, Factorial, Double-blinded, Double-dummy Phase Ⅲ Trial to Evaluate the Efficacy and Safety of the Coadministration of Valsartan 160mg and Rosuvastatin 20mg in Comparison to Each Component Administered Alone in Patients With Hypertension and Hyperlipidemia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Life Sciences</source>
  <oversight_info>
    <authority>Korea: Ministry of Food and Drug Safety</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the efficacy and safety of the coadministration of valsartan
      (Diovan®) 160mg and rosuvastatin (Crestor®) 20mg in comparison to each component
      administered alone in patients with hypertension and hyperlipidemia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>sitDBP changes at Week 8 from baseline</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>sitDBP changes of the valsartan+rosuvastatin and rosuvastatin alone groups at Week 8 from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LDL-C percentage changes at Week 8 from baseline</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>LDL-C percentage changes of the valsartan+rosuvastatin and valsartan alone groups at Week 8 from baseline</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">168</enrollment>
  <condition>Hypertension,</condition>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>Valsartan 160mg, Rosuvastatin 20mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Both Valsartan 160mg and Rosuvastatin 20mg are administered daily by mouth once a day for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valsartan 160mg, Rosuvastatin 20mg placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention : Drug : Both Valsartan 160mg and Rosuvastatin 20mg placebo are administered daily by p.o. once a day for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valsartan 160mg placebo, Rosuvastatin 20mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention : Drug : Both Valsartan 160mg placebo and Rosuvastatin 20mg are administered daily by p.o. once a day for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intervention : Drug : Both Valsartan 160mg placebo  and Rosuvastatin 20mg placebo are administered daily by p.o. once a day for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan 160mg</intervention_name>
    <arm_group_label>Valsartan 160mg, Rosuvastatin 20mg</arm_group_label>
    <arm_group_label>Valsartan 160mg, Rosuvastatin 20mg placebo</arm_group_label>
    <other_name>Diovan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin 20mg</intervention_name>
    <arm_group_label>Valsartan 160mg, Rosuvastatin 20mg</arm_group_label>
    <arm_group_label>Valsartan 160mg placebo, Rosuvastatin 20mg</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan 160mg placebo</intervention_name>
    <arm_group_label>Valsartan 160mg placebo, Rosuvastatin 20mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin 20mg placebo</intervention_name>
    <arm_group_label>Valsartan 160mg, Rosuvastatin 20mg placebo</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient aged 20-80 years who has hypertension and hyperlipidemia

          2. Patient who has a Hypertension

          3. Patient who has a Hyperlipidemia according to NCEP-ATP III guideline(2004)

          4. Patient who signed the Informed Consent Form after receiving an explanation on the
             purpose, methods, and effect of the study

        Exclusion Criteria:

          1. If blood pressure and fasting serum lipid level measured at screening and Visit 2 (0
             week) satisfy the following criteria 1) sitSBP≥180mmHg or  sitDBP≥110mmHg (For high
             risk group,  sitSBP≥ 160mmHg or sitDBP ≥100mmHg ) 2) LDL-C&gt;250mg/dL , or TG≥ 400mg/dL

          2. If sitSBP difference between the right and left arms &gt;20mmHg or sitDBP difference
             between the right and left arms &gt; 10mmHg at screening

          3. When blood pressure is repeatedly measured from the selected arm at screening, if
             sitSBP difference ≥ 20mmHg  or sitDBP difference ≥10mmHg

          4. Patient with orthostatic hypotension accompanying symptoms at screening (decrease in
             sitDBP ≥10mmHg or decrease in sitSBP ≥ 20mmHg )
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Yonsei University Health System Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 26, 2013</lastchanged_date>
  <firstreceived_date>August 5, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Rosuvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
